MeadowBrook Investment Advisors LLC Has $919,000 Position in CVS Health Co. (NYSE:CVS)

MeadowBrook Investment Advisors LLC trimmed its position in CVS Health Co. (NYSE:CVS) by 1.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,611 shares of the pharmacy operator’s stock after selling 256 shares during the period. MeadowBrook Investment Advisors LLC’s holdings in CVS Health were worth $919,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Livelsberger Financial Advisory acquired a new position in shares of CVS Health in the 3rd quarter valued at $31,000. Reston Wealth Management LLC bought a new stake in shares of CVS Health in the third quarter worth about $32,000. First Community Trust NA raised its position in shares of CVS Health by 116.2% during the second quarter. First Community Trust NA now owns 562 shares of the pharmacy operator’s stock worth $33,000 after purchasing an additional 302 shares during the period. Kathleen S. Wright Associates Inc. bought a new position in shares of CVS Health during the 3rd quarter valued at about $33,000. Finally, ORG Partners LLC increased its stake in CVS Health by 11,840.0% during the 2nd quarter. ORG Partners LLC now owns 597 shares of the pharmacy operator’s stock worth $35,000 after purchasing an additional 592 shares in the last quarter. Institutional investors own 80.66% of the company’s stock.

CVS Health Stock Performance

NYSE:CVS traded up $0.20 on Thursday, hitting $54.47. The company’s stock had a trading volume of 1,250,948 shares, compared to its average volume of 11,283,564. The company has a current ratio of 0.80, a quick ratio of 0.59 and a debt-to-equity ratio of 0.80. CVS Health Co. has a one year low of $52.77 and a one year high of $83.25. The stock has a fifty day moving average of $59.41 and a two-hundred day moving average of $58.79. The firm has a market capitalization of $68.55 billion, a P/E ratio of 13.77, a price-to-earnings-growth ratio of 0.94 and a beta of 0.55.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Wednesday, November 6th. The pharmacy operator reported $1.09 EPS for the quarter, topping analysts’ consensus estimates of $1.08 by $0.01. The firm had revenue of $95.43 billion during the quarter, compared to analysts’ expectations of $92.72 billion. CVS Health had a net margin of 1.36% and a return on equity of 10.72%. The company’s revenue for the quarter was up 6.3% compared to the same quarter last year. During the same period in the previous year, the business posted $2.21 earnings per share. Research analysts predict that CVS Health Co. will post 5.44 earnings per share for the current year.

CVS Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Shareholders of record on Monday, October 21st were given a dividend of $0.665 per share. The ex-dividend date of this dividend was Monday, October 21st. This represents a $2.66 annualized dividend and a yield of 4.88%. CVS Health’s dividend payout ratio (DPR) is presently 67.51%.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. TD Cowen upgraded shares of CVS Health from a “hold” rating to a “buy” rating and upped their price target for the company from $59.00 to $85.00 in a report on Friday, October 4th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $62.00 target price on shares of CVS Health in a research note on Tuesday, October 1st. Evercore ISI lifted their price target on CVS Health from $62.00 to $75.00 and gave the company an “outperform” rating in a research note on Tuesday, October 8th. Royal Bank of Canada reiterated an “outperform” rating and set a $68.00 price objective on shares of CVS Health in a report on Wednesday, September 4th. Finally, UBS Group upped their price target on CVS Health from $60.00 to $62.00 and gave the stock a “neutral” rating in a research report on Thursday, November 7th. Nine analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $73.00.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.